Status: Recruiting
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
Participants needed: 55
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Lantheus Medical ImagingUpdated: May 1, 2026Locations: 2
Eligibility criteria
Histopathologic documented diagnosis of R/R osteosarcoma [+15]
Known allergies, hypersensitivity, or intolerance to LNTH-2403 and/or its excipi... [+13]